KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Shares Outstanding (2020 - 2025)

Recursion Pharmaceuticals' Shares Outstanding history spans 6 years, with the latest figure at $528.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 33.11% year-over-year to $528.2 million; the TTM value through Dec 2025 reached $528.2 million, up 33.11%, while the annual FY2025 figure was $528.2 million, 33.11% up from the prior year.
  • Shares Outstanding reached $528.2 million in Q4 2025 per RXRX's latest filing, up from $491.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $528.2 million in Q4 2025 to a low of $24.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $257.5 million, with a median of $211.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: skyrocketed 677.87% in 2021, then grew 2.61% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $170.3 million in 2021, then increased by 12.19% to $191.0 million in 2022, then increased by 22.64% to $234.3 million in 2023, then soared by 69.38% to $396.8 million in 2024, then soared by 33.11% to $528.2 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Shares Outstanding are $528.2 million (Q4 2025), $491.8 million (Q3 2025), and $432.8 million (Q2 2025).